Loading clinical trials...
Loading clinical trials...
A Phase 1, Multiple Ascending Dose Glucose Clamp Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470 in Comparison to Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Hanmi Investigative Site
Chula Vista, California, United States
Start Date
July 28, 2015
Primary Completion Date
April 30, 2018
Completion Date
April 30, 2018
Last Updated
November 6, 2017
60
ACTUAL participants
HM12470
BIOLOGICAL
Lead Sponsor
Hanmi Pharmaceutical Company Limited
NCT05777330
NCT03811470
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03851627